{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T02:20:08Z","timestamp":1719973208133},"reference-count":133,"publisher":"Elsevier","isbn-type":[{"value":"9780323400169","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/b978-0-323-40016-9.00006-3","type":"book-chapter","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T14:36:55Z","timestamp":1527259015000},"page":"135-163","source":"Crossref","is-referenced-by-count":2,"title":["New strategies for the treatment of autoimmune diseases using nanotechnologies"],"prefix":"10.1016","author":[{"given":"Am\u00e9lia M.","family":"Silva","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o R.","family":"Siopa","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Martins-Gomes","sequence":"additional","affiliation":[]},{"given":"Maria C.","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Dario J.","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Dos Anjos Pires","sequence":"additional","affiliation":[]},{"given":"Tatiana","family":"Andreani","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib1","series-title":"Veterinary Immunology","author":"Tizard","year":"2012"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-pathol-020712-163936","article-title":"The influence of innate and adaptive immune responses on atherosclerosis","volume":"9","author":"Witztum","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1681\/ASN.2006050489","article-title":"Toll-like receptors: the interface between innate and adaptive immunity","volume":"17","author":"Tipping","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/B978-0-323-40016-9.00006-3_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneph.2015.175","article-title":"Innate immunity in diabetes and diabetic nephropathy","volume":"12","author":"Wada","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib5","series-title":"Molecular Biology of the Cell","article-title":"The adaptive immune system","author":"Alberts","year":"2007"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib6","series-title":"Kuby Immunology","author":"Kindt","year":"2006"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib7","series-title":"Molecular Biology of the Cell","article-title":"Pathogens, Infection, and Innate Immunity","author":"Alberts","year":"2007"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib8","doi-asserted-by":"crossref","first-page":"A259","DOI":"10.1016\/j.autrev.2009.12.002","article-title":"Definition of human autoimmunity\u2014autoantibodies versus autoimmune disease","volume":"9","author":"Lleo","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib9","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3390\/md13052967","article-title":"Marine polysaccharides from algae with potential biomedical applications","volume":"13","author":"De Jesus Raposo","year":"2015","journal-title":"Marine Drugs"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/hsz-2013-0220","article-title":"Lipid antigens in immunity","volume":"395","author":"Dowds","year":"2014","journal-title":"Biol. Chem."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib11","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1073\/pnas.1502850112","article-title":"Immunomodulatory spherical nucleic acids","volume":"112","author":"Radovic-Moreno","year":"2015","journal-title":"Proc. Natl. Acad. Sci.U.S.A."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0161-5890(87)90015-0","article-title":"Antibody response to haptenic sugar antigen: immunodominancy of protein-bound lactose formed by amino-carbonyl reaction","volume":"24","author":"Matsuda","year":"1987","journal-title":"Mol. Immunol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1476-5381.2009.00151.x","article-title":"The role of histamine H(4) receptor in immune and inflammatory disorders","volume":"157","author":"Zampeli","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib14","doi-asserted-by":"crossref","first-page":"e0132367","DOI":"10.1371\/journal.pone.0132367","article-title":"Histamine induces vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo","volume":"10","author":"Ashina","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.CIR.97.1.99","article-title":"Vascular endothelial growth factor\/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin","volume":"97","author":"Murohara","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib16","series-title":"Cellular and Molecular Immunology","author":"Abbas","year":"2015"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ni.1817","article-title":"Mechanisms maintaining peripheral tolerance","volume":"11","author":"Mueller","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.immuni.2015.04.021","article-title":"Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases","volume":"42","author":"Oftedal","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib19","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","article-title":"Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1","volume":"3","author":"Meager","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/0192623311428481","article-title":"Cellular and molecular mechanisms of autoimmune disease","volume":"40","author":"Bolon","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib21","doi-asserted-by":"crossref","first-page":"A248","DOI":"10.1289\/ehp.119-a248","article-title":"Questions persist: environmental factors in autoimmune disease","volume":"119","author":"Schmidt","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijpharm.2013.12.022","article-title":"In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment","volume":"463","author":"Souza","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2007.08.005","article-title":"Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes","volume":"123","author":"Dubey","year":"2007","journal-title":"J. Control. Release"},{"issue":"Part B","key":"10.1016\/B978-0-323-40016-9.00006-3_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejpb.2014.12.023","article-title":"Current nanotechnology approaches for the treatment and management of diabetic retinopathy","volume":"95","author":"Fangueiro","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib25","first-page":"78","article-title":"Development and characterization of a cationic lipid nanocarrier as non-viral vector for gene therapy","volume":"66","author":"Severino","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2009.08.011","article-title":"Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel","volume":"140","author":"Danhier","year":"2009","journal-title":"J. Control. Release"},{"issue":"Supplement 1","key":"10.1016\/B978-0-323-40016-9.00006-3_bib27","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.nano.2012.05.004","article-title":"Nanomedicines for chronic non-infectious arthritis: the clinician's perspective","volume":"8","author":"Rubinstein","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1542\/peds.2013-1652","article-title":"Genetic and epigenetic factors in etiology of diabetes mellitus type 1","volume":"132","author":"Stankov","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib29","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/S0140-6736(16)30507-4","article-title":"Environmental risk factors for type 1 diabetes","volume":"387","author":"Rewers","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib30","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(16)30582-7","article-title":"Genetic risk factors for type 1 diabetes","volume":"387","author":"Pociot","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/NHH.0000000000000446","article-title":"A review of insulin for the treatment of diabetes mellitus","volume":"34","author":"Freeland","year":"2016","journal-title":"Home Healthc. Now"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5173(01)00614-7","article-title":"Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats","volume":"218","author":"Zhang","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/la051982u","article-title":"Gold nanoparticles as carriers for efficient transmucosal insulin delivery","volume":"22","author":"Joshi","year":"2006","journal-title":"Langmuir"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00592-011-0356-z","article-title":"Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy","volume":"49","author":"Zhao","year":"2012","journal-title":"Acta Diabetologica"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib35","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.biomaterials.2011.10.072","article-title":"A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles","volume":"33","author":"Peng","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib36","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s11095-005-7676-z","article-title":"Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(l-lactide): bioavailability and nasal tolerability in rats","volume":"22","author":"Simon","year":"2005","journal-title":"Pharma. Res."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jbm.b.31161","article-title":"Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin","volume":"88B","author":"Wang","year":"2009","journal-title":"J. Biomed. Mater. Res. Part B"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib38","first-page":"1","article-title":"Insulin-loaded alginic acid nanoparticles for sublingual delivery","volume":"23","author":"Patil","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s13346-014-0205-z","article-title":"Enhanced insulin absorption from sublingual microemulsions: effect of permeation enhancers","volume":"4","author":"Patil","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2009.05.031","article-title":"Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin","volume":"139","author":"Chen","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijpharm.2005.04.016","article-title":"A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats","volume":"298","author":"\u00c7ilek","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2005.01.018","article-title":"Investigation of lectin-modified insulin liposomes as carriers for oral administration","volume":"294","author":"Zhang","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib43","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/bm900035u","article-title":"Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles","volume":"10","author":"Cui","year":"2009","journal-title":"Biomacromolecules"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ejps.2010.08.009","article-title":"Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles","volume":"41","author":"Woitiski","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.12.055","article-title":"HP55-coated capsule containing PLGA\/RS nanoparticles for oral delivery of insulin","volume":"425","author":"Wu","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib46","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1039\/C3PY01416A","article-title":"Oral glucose- and pH-sensitive nanocarriers for simulating insulin release in vivo","volume":"5","author":"Sun","year":"2014","journal-title":"Polym. Chem."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib47","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1464-5491.2003.01076.x","article-title":"Alternative routes of insulin delivery","volume":"20","author":"Owens","year":"2003","journal-title":"Diabetic Med."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib48","first-page":"G467","article-title":"Tight junctions and the molecular basis for regulation of paracellular permeability","volume":"269","author":"Anderson","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib49","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.addr.2007.08.019","article-title":"Current challenges in non-invasive insulin delivery systems: a comparative review","volume":"59","author":"Khafagy","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2012.02.009","article-title":"Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose","volume":"81","author":"Niu","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2013.11.028","article-title":"Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study","volume":"460","author":"Niu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijpharm.2015.05.006","article-title":"Liposomes containing cholesterol analogues of botanical origin as drug delivery systems to enhance the oral absorption of insulin","volume":"489","author":"Cui","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2007.04.004","article-title":"Vesicles from pluronic\/poly(lactic acid) block copolymers as new carriers for oral insulin delivery","volume":"120","author":"Xiong","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2006.10.023","article-title":"Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats","volume":"117","author":"Damg\u00e9","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2007.05.019","article-title":"Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles","volume":"122","author":"Chalasani","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2006.12.003","article-title":"A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin","volume":"117","author":"Chalasani","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib57","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1002\/jps.21347","article-title":"Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response","volume":"97","author":"Reis","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib58","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.biomaterials.2008.12.066","article-title":"In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery","volume":"30","author":"Sonaje","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib59","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1016\/j.biomaterials.2010.01.042","article-title":"Enteric-coated capsules filled with freeze-dried chitosan\/poly(glutamic acid) nanoparticles for oral insulin delivery","volume":"31","author":"Sonaje","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib60","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2217\/nnm.15.36","article-title":"Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles","volume":"10","author":"Chaturvedi","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.carbpol.2015.09.103","article-title":"Positive\/negative surface charge of chitosan based nanogels and its potential influence on oral insulin delivery","volume":"136","author":"Wang","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib62","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.addr.2008.03.012","article-title":"Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers","volume":"60","author":"Slowing","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib63","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1021\/la980380q","article-title":"Formation and adsorption of clusters of gold nanoparticles onto functionalized silica nanoparticle surfaces","volume":"14","author":"Westcott","year":"1998","journal-title":"Langmuir"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0142-9612(03)00566-0","article-title":"Preparation and characterization of porous hollow silica nanoparticles for drug delivery application","volume":"25","author":"Chen","year":"2004","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib65","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.colsurfb.2014.10.047","article-title":"Surface engineering of silica nanoparticles for oral insulin delivery: characterization and cell toxicity studies","volume":"123","author":"Andreani","year":"2014","journal-title":"Colloids Surf. B"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib66","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejpb.2015.03.027","article-title":"Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: interactions with mucin and biomembrane models","volume":"93","author":"Andreani","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib67","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ijpharm.2014.07.049","article-title":"Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery","volume":"473","author":"Andreani","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib68","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2013.06.051","article-title":"Preparation, characterization, and evaluation in vivo of Ins-SiO2-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin","volume":"454","author":"Zhao","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib69","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4081\/dr.2014.5451","article-title":"Progress in psoriasis therapy via novel drug delivery systems","volume":"6","author":"Vincent","year":"2014","journal-title":"Dermatol. Rep."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/09546634.2014.927816","article-title":"Photodynamic therapy for psoriasis","volume":"26","author":"Choi","year":"2015","journal-title":"J. Dermatolog. Treat."},{"issue":"725-33","key":"10.1016\/B978-0-323-40016-9.00006-3_bib71","first-page":"736","article-title":"Treatment of psoriasis: an algorithm-based approach for primary care physicians","volume":"61","author":"Pardasani","year":"2000","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib72","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/jid.2011.53","article-title":"Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways","volume":"131","author":"Racz","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib73","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(94)91883-X","article-title":"Treatment of psoriasis by topical photodynamic therapy with polychromatic light","volume":"343","author":"Boehncke","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2165\/00003088-198510010-00002","article-title":"Clinical pharmacokinetics of the retinoids","volume":"10","author":"Lucek","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib76","first-page":"241","article-title":"Stability of hydrophilic gels of tretinoin","volume":"110","author":"Lucero","year":"1994","journal-title":"Int. J. Pharm. Pharmacol. Commun."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.clindermatol.2004.03.013","article-title":"Comparison of topical retinoids in the treatment of acne","volume":"22","author":"Rigopoulos","year":"2004","journal-title":"Clin. Dermatol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib78","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2006.08.007","article-title":"Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery","volume":"328","author":"Liu","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib79","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2007.05.061","article-title":"Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery","volume":"345","author":"Shah","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2008.06.028","article-title":"Development of SLNs from natural lipids: application to topical deliver y of tretinoin","volume":"363","author":"Mandawgade","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijpharm.2009.07.025","article-title":"Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles","volume":"381","author":"Castro","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib82","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.colsurfb.2011.11.051","article-title":"Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin","volume":"93","author":"Ridolfi","year":"2012","journal-title":"Colloids Surf. B"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib83","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpb.2007.01.015","article-title":"Cetyl palmitate-based NLC for topical delivery of coenzyme Q10\u2014development, physicochemical characterization and in vitro release studies","volume":"67","author":"Teeranachaideekul","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2014.10.033","article-title":"The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model","volume":"197","author":"Gainza","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib85","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijpharm.2012.08.040","article-title":"Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation","volume":"439","author":"Han","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib86","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) in cosmetic and dermatological preparations","volume":"54","author":"M\u00fcller","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2004.02.032","article-title":"Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery","volume":"278","author":"Souto","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib88","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2010.09.007","article-title":"Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis","volume":"401","author":"Agrawal","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib89","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ijpharm.2014.10.067","article-title":"A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers","volume":"477","author":"Pinto","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib90","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.steroids.2015.05.012","article-title":"Design, characterization and skin permeating potential of fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis","volume":"101","author":"Pradhan","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib91","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2013.08.019","article-title":"Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity","volume":"456","author":"Raza","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-5173(01)00810-9","article-title":"Preparation and in vitro evaluation of liposomal\/niosomal delivery systems for antipsoriatic drug dithranol","volume":"228","author":"Agarwal","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijpharm.2012.01.045","article-title":"Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment","volume":"427","author":"Srisuk","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/B978-0-323-40016-9.00006-3_bib94","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/1389200218666170222145240","article-title":"Nanocarriers mediated topical drug delivery for psoriasis treatment","volume":"18","author":"Gungor","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib95","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib96","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.1303258","article-title":"Activation of the STING adaptor attenuates experimental autoimmune encephalitis","volume":"192","author":"Lemos","year":"2014","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/B978-0-323-40016-9.00006-3_bib97","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/eji.201646485","article-title":"Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis","volume":"46","author":"Martin","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib98","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib99","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mce.2007.03.007","article-title":"Glucocorticoids in the control of neuroinflammation","volume":"275","author":"Tischner","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib101","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/brain\/awg176","article-title":"Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis","volume":"126","author":"Schmidt","year":"2003","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib102","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.expneurol.2008.02.005","article-title":"Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations","volume":"211","author":"Linker","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib103","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1046\/j.1471-4159.1997.69052064.x","article-title":"Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis","volume":"69","author":"Ferrante","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib104","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jneuroim.2009.05.019","article-title":"Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis","volume":"213","author":"Kizelsztein","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib105","doi-asserted-by":"crossref","first-page":"e0130442","DOI":"10.1371\/journal.pone.0130442","article-title":"Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases","volume":"10","author":"Turjeman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib106","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1021\/nn403743b","article-title":"Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain","volume":"7","author":"Heckman","year":"2013","journal-title":"ACS Nano."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib107","doi-asserted-by":"crossref","first-page":"14085","DOI":"10.1021\/bi0203987","article-title":"DNA nanoparticles and development of DNA delivery vehicles for gene therapy","volume":"41","author":"Vijayanathan","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib108","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/10837450.2016.1226901","article-title":"Solid lipid nanoparticles surface modified with anti-Contactin-2 or anti-Neurofascin for brain-targeted delivery of medicines","volume":"22","author":"Gandomi","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib109","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1590\/abd1806-4841.20142146","article-title":"Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects","volume":"89","author":"Moura Filho","year":"2014","journal-title":"Anais Brasileiros de Dermatologia"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib111","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0961203316636468","article-title":"A liposomal steroid nano-drug for treating systemic lupus erythematosus","volume":"25","author":"Moallem","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib112","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1172\/JCI65907","article-title":"Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice","volume":"123","author":"Look","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib113","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.biomaterials.2013.10.046","article-title":"The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus","volume":"35","author":"Look","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib114","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fphys.2017.00508","article-title":"Inhibition of Toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/exd.12035","article-title":"Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls","volume":"21","author":"Patsinakidis","year":"2012","journal-title":"Exp. Dermatol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib116","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib117","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/BOR.0b013e32834518a3","article-title":"Pathophysiology of rheumatoid arthritis","volume":"23","author":"Cooles","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib118","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00296-010-1644-6","article-title":"The swollen joint, the thickened artery, and the smoking gun: tobacco exposure, citrullination and rheumatoid arthritis","volume":"31","author":"Serra-Bonett","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib120","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2217\/nnm.15.45","article-title":"Nanomedicine delivers promising treatments for rheumatoid arthritis","volume":"10","author":"Prasad","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib121","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K","article-title":"Synovial macrophage depletion with clodronate containing liposomes in rheumatoid arthritis","volume":"43","author":"Barrera","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib122","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0022-1759(96)00056-7","article-title":"Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine","volume":"193","author":"Van Rooijen","year":"1996","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib123","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/40.9.978","article-title":"Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate","volume":"40","author":"Richards","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib124","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(94)90012-4","article-title":"Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications","volume":"174","author":"Van Rooijen","year":"1994","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib125","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.11140","article-title":"Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes","volume":"48","author":"Metselaar","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib126","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/art.21719","article-title":"Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis","volume":"54","author":"Koning","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib127","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1525-0016(03)00181-3","article-title":"Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium","volume":"8","author":"Mi","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2014.01.005","article-title":"Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis","volume":"151","author":"Vanniasinghe","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood-2008-04-150789","article-title":"A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages","volume":"113","author":"Xia","year":"2009","journal-title":"Blood"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib130","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1021\/acs.biomac.5b00823","article-title":"Peptide anchor for folate-targeted liposomal delivery","volume":"16","author":"Nogueira","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib131","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1166\/jbn.2015.2170","article-title":"Enhancing methotrexate tolerance with folate tagged liposomes in arthritic mice","volume":"11","author":"Nogueira","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib132","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00262-011-1040-4","article-title":"Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity","volume":"60","author":"H\u00e4usler","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/B978-0-323-40016-9.00006-3_bib133","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejps.2013.09.013","article-title":"Synthesis and evaluation of cyclosporine A-loaded polysialic acid\u2013polycaprolactone micelles for rheumatoid arthritis","volume":"51","author":"Wilson","year":"2014","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Emerging Nanotechnologies in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323400169000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323400169000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T13:20:11Z","timestamp":1534857611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323400169000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780323400169"],"references-count":133,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-40016-9.00006-3","relation":{},"subject":[],"published":{"date-parts":[[2018]]}}}